Royalty Report: Drugs, Biotechnology, Therapeutic – Collection: 26640


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Biotechnology
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26640

License Grant
Japanese Licensor hereby grants an exclusive licence to Canadian Licensee to market and produce the Products.
License Property
The Products shall comprise, but not be limited to, the following
·Recombinant Human Interferon alpha-2a (rHulFN-a 2a) and alpha-2b (rHulFN-a 2b)
·Recombinant Human granulocyte colony stimulating factor (rHuG-CSF);
·Recombinant Human granulocyte macrophage colony stimulating factor (rHuGM-CSF);
·Interleukin 2
·EPO (erythropoietin)

The Company has acquired license to patented technologies related to the production of therapeutic proteins, alpha and beta interferon, Interleukin 2, EPO (erythropoietin) and human growth factors (rHuG-CSF and rHuGM-CSF).

Field of Use
Field of Use relates to the medical industry.

IPSCIO Record ID: 25941

License Grant
The Agreement, dated as of July 25, 2003,  for sales of Increlex, a DNA-derived recombinant human insulin-like growth factor-1 (rhIGF-1), and of any drug that combines rhIGF-1 and IGF binding protein-3.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 655

License Grant
The Licensor hereby grants to the Licensee, an exclusive license to make in one location, have made and use Licensed Know-how, Patents and Products in the Licensed Territory  in the licensed field and to sell Licensed Products in the Licensed Territory.

Products shall mean IL-2, Hepatitis B, and EPO for all human uses in the licensed field.

License Property
Hepatitis B shall mean the recombinant yeast-derived hepatitis B surface antigen vaccine.

IL-2 shall mean the recombinant-methionyl human interleukin 2[alanine 125].

Field of Use
Licensed field shall mean and include (a) with respect to EPO all indications for human use except dialysis and diagnostics.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.